Morgan W T, Alam J, Deaciuc V, Muster P, Tatum F M, Smith A
Department of Biochemistry and Molecular Biology, Louisiana State University Medical Center, New Orleans 70112.
J Biol Chem. 1988 Jun 15;263(17):8226-31.
Sn-protoporphyrin IX (SnPP), an inhibitor of heme oxygenase and a potential therapeutic agent for neonatal hyperbilirubinemia, is bound tightly by hemopexin. The apparent dissociation constant (Kd) at pH 7.4 is 0.25 +/- 0.15 microM, but estimation of the Kd for the SnPP-hemopexin complex is hampered by the fact that at physiological pH SnPP exists as monomers and dimers, both of which are bound by hemopexin. SnPP is readily displaced from hemopexin by heme (Kd less than 1 pM). The hemopexin-SnPP interaction, like that of heme-hemopexin, is dependent on the histidine residues of hemopexin. However, as expected from the differences in the coordination chemistries of tin and iron, the stability of the histidyl-metalloporphyrin complex is lower for SnPP-hemopexin than for mesoheme-hemopexin. Nevertheless, when SnPP binds to hemopexin, certain of the ligand-induced changes in the conformation of hemopexin which increase the affinity of the protein for its receptor are produced. Binding of SnPP produces the conformational change in hemopexin which protects the hinge region of hemopexin from proteolysis, but SnPP does not produce the characteristic increase in the ellipticity of hemopexin at 231 nm that heme does. Competition experiments confirmed that human serum albumin (apparent Kd = 4 +/- 2 microM) has a significantly lower affinity for SnPP than does hemopexin. Appreciable amounts of SnPP (up to 35% in adults and 20% in neonates) would be bound by hemopexin in the circulation, and the remainder of SnPP would be associated with albumin due to the latter's high concentration in serum. Essentially no non-protein-bound SnPP is present. Importantly, SnPP-hemopexin binds to the hemopexin receptor on mouse hepatoma cells with an affinity comparable to that of heme-hemopexin and treatment of the hepatoma cells with SnPP-hemopexin causes a rapid increase in the steady state level of heme oxygenase messenger RNA. These results show that hemopexin participates in the transport of SnPP to heme oxygenase and in its regulation by SnPP.
锡原卟啉IX(SnPP)是血红素加氧酶的抑制剂,也是新生儿高胆红素血症的一种潜在治疗药物,它能与血红素结合蛋白紧密结合。在pH 7.4时,其表观解离常数(Kd)为0.25±0.15微摩尔,但由于在生理pH条件下SnPP以单体和二聚体形式存在,且二者均可与血红素结合蛋白结合,这一事实阻碍了对SnPP - 血红素结合蛋白复合物Kd的估算。血红素能轻易地将SnPP从血红素结合蛋白上置换下来(Kd小于1皮摩尔)。血红素结合蛋白与SnPP的相互作用,如同血红素与血红素结合蛋白的相互作用一样,依赖于血红素结合蛋白的组氨酸残基。然而,正如从锡和铁配位化学差异所预期的那样,SnPP - 血红素结合蛋白的组氨酸 - 金属卟啉复合物的稳定性低于中血红素 - 血红素结合蛋白。尽管如此,当SnPP与血红素结合蛋白结合时,会产生某些由配体诱导的血红素结合蛋白构象变化,这些变化会增加该蛋白对其受体的亲和力。SnPP的结合会使血红素结合蛋白发生构象变化,从而保护血红素结合蛋白的铰链区不被蛋白酶水解,但SnPP不会像血红素那样使血红素结合蛋白在231纳米处的椭圆率产生特征性增加。竞争实验证实,人血清白蛋白(表观Kd = 4±2微摩尔)对SnPP的亲和力明显低于血红素结合蛋白。循环中的血红素结合蛋白会结合相当数量的SnPP(成年人中高达35%,新生儿中为20%),由于血清中白蛋白浓度很高,其余的SnPP会与白蛋白结合。基本上不存在未与蛋白结合的SnPP。重要的是,SnPP - 血红素结合蛋白与小鼠肝癌细胞上的血红素结合蛋白受体结合,其亲和力与血红素 - 血红素结合蛋白相当,用SnPP - 血红素结合蛋白处理肝癌细胞会导致血红素加氧酶信使核糖核酸的稳态水平迅速升高。这些结果表明,血红素结合蛋白参与了SnPP向血红素加氧酶的转运及其对SnPP的调节。